Global Viral Vector and Plasmid DNA Manufacturing Market – Industry Analysis and Forecast (2019-2026) – By Type, Application, Disease, End-User and Region.

Global Viral Vector and Plasmid DNA Manufacturing Market – Industry Analysis and Forecast (2019-2026) – By Type, Application, Disease, End-User and Region.

Market Scenario

Global Viral Vector and Plasmid DNA Manufacturing Market was valued US$ 1.5Bn in 2018 and is expected to reach 5.2Bn by 2026, at a CAGR of 16.81% during a forecast period. Market: Overview Viral and non-viral vectors have emerged as a well-organized delivery mechanism for expansion of innovative medicines. Growth of optimized large-scale production, harvest, and purification strategies play an essential role in achieving observance with regulatory requirements in context to product purity and traceability. This also aids in increase of rate of healing development from clinical estimate step to market approval. Vector manufacturing is considered as the most composite and resource-intensive process in the manufacturing of products such as gene therapies and vaccines. Moreover, significant improvements are witnessed with introduction of new protocols. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. Global Viral Vector and Plasmid DNA Manufacturing Market: Drivers and Restraints Enhancing in occurrence and frequency rates of cancer, genetic disorders and infectious diseases, high unmet needs in patients with unusual disorders, and raised acceptance for comparatively newer treatment options in developing countries are expected to be major drivers of the global Viral Vector and Plasmid DNA Manufacturing Market during the forecast period. Global Viral Vector and Plasmid DNA Manufacturing Market: Segment Analysis On the basis of application segment, the global market has been classified into gene therapy, vaccinology, and others. The gene therapy segment follows the Viral Vector and Plasmid DNA Manufacturing Market, in provision of value. This is mainly accredited to the increasing acceptance of gene therapy products for the treatment of rare disorders all over the globe and accessibility of accepted gene therapy products. The vaccinology segment is projected to expand at a significant CAGR (XX %) during the forecast period. The development is accredited to the increased research initiatives for viral vector based vaccines which leads to increase in growth of Viral Vector and Plasmid DNA Manufacturing Market. Global Viral Vector and Plasmid DNA Manufacturing Market: Regional Analysis In the geographical area, North America is expected to increase the growth of the global Viral Vector and Plasmid DNA Manufacturing Market during forecast period, owing to the high acceptance of viral vector-based products in the U.S., enlarged prevalence of cancer and monogenic disorders, rich product pipeline, and technological advancements in the region. The market in Asia Pacific is predicted to expand at a considerably high CAGR (XX %) during the forecast period, owing to the increased research initiatives in countries such as India and accessibility of approved gene therapies based on viral vectors in countries such as China and Japan. The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Viral Vector and Plasmid DNA Manufacturing Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTER’s analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Viral Vector and Plasmid DNA Manufacturing Market.

Scope of Global Viral Vector and Plasmid DNA Manufacturing Market:

Global Viral Vector and Plasmid DNA Manufacturing Market, by Type

• Lent virus • Adenovirus • Adeno-Associated Virus (AAV) • Plasmid DNA • Others

Global Viral Vector and Plasmid DNA Manufacturing Market, by Application

• Gene Therapy • Vaccinology • Others

Global Viral Vector and Plasmid DNA Manufacturing Market, by Disease

• Genetic Disorders • Cancer • Infectious Disease • Others

Global Viral Vector and Plasmid DNA Manufacturing Market, by End-User

• Biotech Companies • Research Institutes

Global Viral Vector and Plasmid DNA Manufacturing Market, by Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Viral Vector and Plasmid DNA Manufacturing Market

• CobraBiologics, Novasep Inc • Cell and Gene Therapy Catapult • Kaneka Eurogentec S.A. • FUJIFILM Diosynth Biotechnologies Inc. • Spark Therapeutics, Inc • Merck KGaA • uniQure N.V. • Lonza.

Table of Contents

Global Viral Vector and Plasmid DNA Manufacturing Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Viral Vector and Plasmid DNA Manufacturing Market, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends in Global Viral Vector and Plasmid DNA Manufacturing Market 4.8. Global Viral Vector and Plasmid DNA Manufacturing Market Competitive Landscape 5. Supply Side and Demand Side Indicators 6. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast 6.1. Global Viral Vector and Plasmid DNA Manufacturing Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Type 7.4. Global Viral Vector and Plasmid DNA Manufacturing Market Size (US$ Bn) Forecast, by Type 7.5. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Type 7.6. Global Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis, by Type 8. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast, by Disease 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Disease 8.4. Global Viral Vector and Plasmid DNA Manufacturing Market Size (US$ Bn) Forecast, by Disease 8.5. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Disease 8.6. Global Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis, by Disease 9. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast, by Application 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Application 9.4. Global Viral Vector and Plasmid DNA Manufacturing Market Size (US$ Bn) Forecast, by Application 9.5. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Application 9.6. Global Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis, by Application 10. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis and Forecast, by End-User 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by End-User 10.4. Global Viral Vector and Plasmid DNA Manufacturing Market Size (US$ Bn) Forecast, by End-User 10.5. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis, by End-User 10.6. Global Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis, by End-User 11. Global Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Region 11.1. Global Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Region 11.2. Global Viral Vector and Plasmid DNA Manufacturing Market Size (US$ Bn) Forecast, by Region 11.3. Global Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis, by Region 12. North America Viral Vector and Plasmid DNA Manufacturing Market Analysis 12.1. Key Findings 12.2. North America Viral Vector and Plasmid DNA Manufacturing Market Overview 12.3. North America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Type 12.4. North America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 12.4.1. Lent virus 12.4.2. Adenovirus 12.4.3. Adeno-Associated Virus (AAV) 12.4.4. Plasmid DNA 12.4.5. Others 12.5. North America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Disease 12.6. North America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 12.6.1. Genetic Disorders 12.6.2. Cancer 12.6.3. Infectious Disease 12.6.4. Others 12.7. North America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Application 12.8. North America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 12.8.1. Gene Therapy 12.8.2. Vaccinology 12.8.3. Others 12.9. North America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by End-User 12.10. North America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 12.10.1. Biotech Companies 12.10.2. Research Institutes 12.11. North America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Country 12.12. North America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Country 12.14. U.S. Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 12.14.1. Lent virus 12.14.2. Adenovirus 12.14.3. Adeno-Associated Virus (AAV) 12.14.4. Plasmid DNA 12.14.5. Others 12.15. U.S. Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 12.15.1. Genetic Disorders 12.15.2. Cancer 12.15.3. Infectious Disease 12.15.4. Others 12.16. U.S. Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 12.16.1. Gene Therapy 12.16.2. Vaccinology 12.16.3. Others 12.17. U.S. Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 12.17.1. Biotech Companies 12.17.2. Research Institutes 12.18. Canada Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 12.18.1. Lent virus 12.18.2. Adenovirus 12.18.3. Adeno-Associated Virus (AAV) 12.18.4. Plasmid DNA 12.18.5. Others 12.19. Canada Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 12.19.1. Genetic Disorders 12.19.2. Cancer 12.19.3. Infectious Disease 12.19.4. Others 12.20. Canada Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 12.20.1. Gene Therapy 12.20.2. Vaccinology 12.20.3. Others 12.21. Canada Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 12.21.1. Biotech Companies 12.21.2. Research Institutes 12.22. North America Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis 12.22.1. By Type 12.22.2. By Disease 12.22.3. By Application 12.22.4. By End-User 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Development 13. Europe Viral Vector and Plasmid DNA Manufacturing Market Analysis 13.1. Key Findings 13.2. Europe Viral Vector and Plasmid DNA Manufacturing Market Overview 13.3. Europe Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Type 13.4. Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 13.4.1. Lent virus 13.4.2. Adenovirus 13.4.3. Adeno-Associated Virus (AAV) 13.4.4. Plasmid DNA 13.4.5. Others 13.5. Europe Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Disease 13.6. Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 13.6.1. Genetic Disorders 13.6.2. Cancer 13.6.3. Infectious Disease 13.6.4. Others 13.7. Europe Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Application 13.8. Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 13.8.1. Gene Therapy 13.8.2. Vaccinology 13.8.3. Others 13.9. Europe Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by End-User 13.10. Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 13.10.1. Biotech Companies 13.10.2. Research Institutes 13.11. Others Europe Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Country 13.12. Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Country 13.14. Germany Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 13.14.1. Lent virus 13.14.2. Adenovirus 13.14.3. Adeno-Associated Virus (AAV) 13.14.4. Plasmid DNA 13.14.5. Others 13.15. Germany Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 13.15.1. Genetic Disorders 13.15.2. Cancer 13.15.3. Infectious Disease 13.15.4. Others 13.16. Germany Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 13.16.1. Gene Therapy 13.16.2. Vaccinology 13.16.3. Others 13.17. Germany Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 13.17.1. Biotech Companies 13.17.2. Research Institutes 13.18. U.K. Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 13.18.1. Lent virus 13.18.2. Adenovirus 13.18.3. Adeno-Associated Virus (AAV) 13.18.4. Plasmid DNA 13.18.5. Others 13.19. U.K. Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 13.19.1. Genetic Disorders 13.19.2. Cancer 13.19.3. Infectious Disease 13.19.4. Others 13.20. U.K. Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 13.20.1. Gene Therapy 13.20.2. Vaccinology 13.20.3. Others 13.21. U.K. Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 13.21.1. Biotech Companies 13.21.2. Research Institutes 13.22. France Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 13.22.1. Lent virus 13.22.2. Adenovirus 13.22.3. Adeno-Associated Virus (AAV) 13.22.4. Plasmid DNA 13.22.5. Others 13.23. France Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 13.23.1. Genetic Disorders 13.23.2. Cancer 13.23.3. Infectious Disease 13.23.4. Others 13.24. France Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 13.24.1. Gene Therapy 13.24.2. Vaccinology 13.24.3. Others 13.25. France Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 13.25.1. Biotech Companies 13.25.2. Research Institutes 13.26. Italy Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 13.26.1. Lent virus 13.26.2. Adenovirus 13.26.3. Adeno-Associated Virus (AAV) 13.26.4. Plasmid DNA 13.26.5. Others 13.27. Italy Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 13.27.1. Genetic Disorders 13.27.2. Cancer 13.27.3. Infectious Disease 13.27.4. Others 13.28. Italy Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 13.28.1. Gene Therapy 13.28.2. Vaccinology 13.28.3. Others 13.29. Italy Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 13.29.1. Biotech Companies 13.29.2. Research Institutes 13.30. Spain Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 13.30.1. Lent virus 13.30.2. Adenovirus 13.30.3. Adeno-Associated Virus (AAV) 13.30.4. Plasmid DNA 13.30.5. Others 13.31. Spain Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 13.31.1. Genetic Disorders 13.31.2. Cancer 13.31.3. Infectious Disease 13.31.4. Others 13.32. Spain Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 13.32.1. Gene Therapy 13.32.2. Vaccinology 13.32.3. Others 13.33. Spain Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 13.33.1. Biotech Companies 13.33.2. Research Institutes 13.34. Rest of Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 13.34.1. Lent virus 13.34.2. Adenovirus 13.34.3. Adeno-Associated Virus (AAV) 13.34.4. Plasmid DNA 13.34.5. Others 13.35. Rest of Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 13.35.1. Genetic Disorders 13.35.2. Cancer 13.35.3. Infectious Disease 13.35.4. Others 13.36. Rest of Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 13.36.1. Gene Therapy 13.36.2. Vaccinology 13.36.3. Others 13.37. Rest Of Europe Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 13.37.1. Biotech Companies 13.37.2. Research Institutes 13.38. Europe Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis 13.38.1. By Type 13.38.2. By Disease 13.38.3. By Application 13.38.4. By End-User 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Development 14. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Analysis 14.1. Key Findings 14.2. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Overview 14.3. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Type 14.4. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 14.4.1. Lent virus 14.4.2. Adenovirus 14.4.3. Adeno-Associated Virus (AAV) 14.4.4. Plasmid DNA 14.4.5. Others 14.5. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Disease 14.6. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 14.6.1. Genetic Disorders 14.6.2. Cancer 14.6.3. Infectious Disease 14.6.4. Others 14.7. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Application 14.8. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 14.8.1. Gene Therapy 14.8.2. Vaccinology 14.8.3. Others 14.9. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by End-User 14.10. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 14.10.1. Biotech Companies 14.10.2. Research Institutes 14.11. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Country 14.12. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Country 14.14. China Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 14.14.1. Lent virus 14.14.2. Adenovirus 14.14.3. Adeno-Associated Virus (AAV) 14.14.4. Plasmid DNA 14.14.5. Others 14.15. China Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 14.15.1. Genetic Disorders 14.15.2. Cancer 14.15.3. Infectious Disease 14.15.4. Others 14.16. China Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 14.16.1. Gene Therapy 14.16.2. Vaccinology 14.16.3. Others 14.17. China Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 14.17.1. Biotech Companies 14.17.2. Research Institutes 14.18. India Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 14.18.1. Lent virus 14.18.2. Adenovirus 14.18.3. Adeno-Associated Virus (AAV) 14.18.4. Plasmid DNA 14.18.5. Others 14.19. India Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 14.19.1. Genetic Disorders 14.19.2. Cancer 14.19.3. Infectious Disease 14.19.4. Others 14.20. India Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 14.20.1. Gene Therapy 14.20.2. Vaccinology 14.20.3. Others 14.21. India Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 14.21.1. Biotech Companies 14.21.2. Research Institutes 14.22. Japan Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 14.22.1. Lent virus 14.22.2. Adenovirus 14.22.3. Adeno-Associated Virus (AAV) 14.22.4. Plasmid DNA 14.22.5. Others 14.23. Japan Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 14.23.1. Genetic Disorders 14.23.2. Cancer 14.23.3. Infectious Disease 14.23.4. Others 14.24. Japan Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 14.24.1. Gene Therapy 14.24.2. Vaccinology 14.24.3. Others 14.25. Japan Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 14.25.1. Biotech Companies 14.25.2. Research Institutes 14.26. ASEAN Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 14.26.1. Lent virus 14.26.2. Adenovirus 14.26.3. Adeno-Associated Virus (AAV) 14.26.4. Plasmid DNA 14.26.5. Others 14.27. ASEAN Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 14.27.1. Genetic Disorders 14.27.2. Cancer 14.27.3. Infectious Disease 14.27.4. Others 14.28. ASEAN Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 14.28.1. Gene Therapy 14.28.2. Vaccinology 14.28.3. Others 14.29. ASEAN Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 14.29.1. Biotech Companies 14.29.2. Research Institutes 14.30. Rest of Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 14.30.1. Lent virus 14.30.2. Adenovirus 14.30.3. Adeno-Associated Virus (AAV) 14.30.4. Plasmid DNA 14.30.5. Others 14.31. Rest of Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 14.31.1. Genetic Disorders 14.31.2. Cancer 14.31.3. Infectious Disease 14.31.4. Others 14.32. Rest of Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 14.32.1. Gene Therapy 14.32.2. Vaccinology 14.32.3. Others 14.33. Rest of Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 14.33.1. Biotech Companies 14.33.2. Research Institutes 14.34. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis 14.34.1. By Type 14.34.2. By Disease 14.34.3. By Application 14.34.4. By End-User 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Development 15. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Overview 15.3. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Type 15.4. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 15.4.1. Lent virus 15.4.2. Adenovirus 15.4.3. Adeno-Associated Virus (AAV) 15.4.4. Plasmid DNA 15.4.5. Others 15.5. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Disease 15.6. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 15.6.1. Genetic Disorders 15.6.2. Cancer 15.6.3. Infectious Disease 15.6.4. Others 15.7. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Application 15.8. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 15.8.1. Gene Therapy 15.8.2. Vaccinology 15.8.3. Others 15.9. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by End-User 15.10. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 15.10.1. Biotech Companies 15.10.2. Research Institutes 15.11. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Country 15.12. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Country 15.14. GCC Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 15.14.1. Lent virus 15.14.2. Adenovirus 15.14.3. Adeno-Associated Virus (AAV) 15.14.4. Plasmid DNA 15.14.5. Others 15.15. GCC Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 15.15.1. Genetic Disorders 15.15.2. Cancer 15.15.3. Infectious Disease 15.15.4. Others 15.16. GCC Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 15.16.1. Gene Therapy 15.16.2. Vaccinology 15.16.3. Others 15.17. GCC Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 15.17.1. Biotech Companies 15.17.2. Research Institutes 15.18. South Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 15.18.1. Lent virus 15.18.2. Adenovirus 15.18.3. Adeno-Associated Virus (AAV) 15.18.4. Plasmid DNA 15.18.5. Others 15.19. South Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 15.19.1. Genetic Disorders 15.19.2. Cancer 15.19.3. Infectious Disease 15.19.4. Others 15.20. South Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 15.20.1. Gene Therapy 15.20.2. Vaccinology 15.20.3. Others 15.21. South Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 15.21.1. Biotech Companies 15.21.2. Research Institutes 15.22. Rest of Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 15.22.1. Lent virus 15.22.2. Adenovirus 15.22.3. Adeno-Associated Virus (AAV) 15.22.4. Plasmid DNA 15.22.5. Others 15.23. Rest of Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 15.23.1. Genetic Disorders 15.23.2. Cancer 15.23.3. Infectious Disease 15.23.4. Others 15.24. Rest of Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 15.24.1. Gene Therapy 15.24.2. Vaccinology 15.24.3. Others 15.25. Rest of Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 15.25.1. Biotech Companies 15.25.2. Research Institutes 15.26. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis 15.26.1. By Type 15.26.2. By Disease 15.26.3. By Application 15.26.4. By End-User 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Development 16. South America Viral Vector and Plasmid DNA Manufacturing Market Analysis 16.1. Key Findings 16.2. South America Viral Vector and Plasmid DNA Manufacturing Market Overview 16.3. South America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Type 16.4. South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 16.4.1. Lent virus 16.4.2. Adenovirus 16.4.3. Adeno-Associated Virus (AAV) 16.4.4. Plasmid DNA 16.4.5. Others 16.5. South America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Disease 16.6. South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 16.6.1. Genetic Disorders 16.6.2. Cancer 16.6.3. Infectious Disease 16.6.4. Others 16.7. South America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Application 16.8. South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 16.8.1. Gene Therapy 16.8.2. Vaccinology 16.8.3. Others 16.9. South America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by End-User 16.10. South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 16.10.1. Biotech Companies 16.10.2. Research Institutes 16.11. South America Viral Vector and Plasmid DNA Manufacturing Market Value Share Analysis, by Country 16.12. South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Viral Vector and Plasmid DNA Manufacturing Market Analysis, by Country 16.14. Brazil Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 16.14.1. Lent virus 16.14.2. Adenovirus 16.14.3. Adeno-Associated Virus (AAV) 16.14.4. Plasmid DNA 16.14.5. Others 16.15. Brazil Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 16.15.1. Genetic Disorders 16.15.2. Cancer 16.15.3. Infectious Disease 16.15.4. Others 16.16. Brazil Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 16.16.1. Gene Therapy 16.16.2. Vaccinology 16.16.3. Others 16.17. Brazil Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 16.17.1. Biotech Companies 16.17.2. Research Institutes 16.18. Mexico Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 16.18.1. Lent virus 16.18.2. Adenovirus 16.18.3. Adeno-Associated Virus (AAV) 16.18.4. Plasmid DNA 16.18.5. Others 16.19. Mexico Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 16.19.1. Genetic Disorders 16.19.2. Cancer 16.19.3. Infectious Disease 16.19.4. Others 16.20. Mexico Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 16.20.1. Gene Therapy 16.20.2. Vaccinology 16.20.3. Others 16.21. Mexico Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 16.21.1. Biotech Companies 16.21.2. Research Institutes 16.22. Rest of South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Type 16.22.1. Lent virus 16.22.2. Adenovirus 16.22.3. Adeno-Associated Virus (AAV) 16.22.4. Plasmid DNA 16.22.5. Others 16.23. Rest of South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Disease 16.23.1. Genetic Disorders 16.23.2. Cancer 16.23.3. Infectious Disease 16.23.4. Others 16.24. Rest of South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by Application 16.24.1. Gene Therapy 16.24.2. Vaccinology 16.24.3. Others 16.25. Rest of South America Viral Vector and Plasmid DNA Manufacturing Market Forecast, by End-User 16.25.1. Biotech Companies 16.25.2. Research Institutes 16.26. South America Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis 16.26.1. By Type 16.26.2. By Disease 16.26.3. By Application 16.26.4. By End-User 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Development 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Ingredients and R&D investment 17.2.2. New Asset Type Launches and Asset Type Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Ingredients 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Cobra Biologics 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Asset Type Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Company Footprint 17.3.2. Novasep Inc 17.3.3. Cell and Gene Therapy Catapult 17.3.4. Kaneka Eurogentec S.A. 17.3.5. FUJIFILM Diosynth Biotechnologies Inc. 17.3.6. Spark Therapeutics, Inc 17.3.7. Merck KGaA 17.3.8. uniQure N.V. 17.3.9. Lonza. 18. Primary Key Insights

About This Report

Report ID32167
Category Biotechnology
Published DateJuly 2019
No of Pages210
Contact Us